Back to top
more

Align Technology (ALGN)

(Delayed Data from NSDQ)

$271.70 USD

271.70
729,847

-8.69 (-3.10%)

Updated May 10, 2024 04:00 PM ET

After-Market: $271.68 -0.02 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (151 out of 251)

Industry: Medical - Dental Supplies

Better trading starts here.

Zacks News

Align Technology, based in California, manufactures and markets a system of clear aligner therapy, intra-oral scanners and CAD/CAM (computer-aided design and computer-aided manufacturing) digital services used in dentistry, orthodontics, and dental records storage. The clear aligner system corrects malocclusion using nearly invisible and removable appliances that gently move the tooth to a desired final position.

Neogen (NEOG) Faces Macroeconomic Issues, Fierce Competition

Neogen (NEOG) faces intense competition from companies ranging from small businesses to divisions of large multinational companies.

AMN Healthcare (AMN) Q1 Earnings and Revenues Beat Estimates

AMN Healthcare's (AMN) dismal results in the majority of its segments led to a soft overall first-quarter performance.

PacBio (PACB) Q1 Earnings In Line, Adjusted Gross Margin Up

PacBio (PACB) reports growth in Product revenues in the first quarter of 2024. However, Instruments revenues decline year over year due to lower shipment of Revio units.

Catalent (CTLT) Q3 Earnings Lag Estimates, Gross Margin Up

Catalent (CTLT) reports a solid revenue uptick in third-quarter fiscal 2024 despite lower revenues in Biologics segments.

Inogen (INGN) Q1 Earnings Top Estimates, Revenues Up Y/Y

Higher business-to-business sales aid Inogen's (INGN) overall first-quarter results.

QuidelOrtho (QDEL) Q1 Earnings Beat Estimates, Margins Fall

QuidelOrtho's (QDEL) first-quarter results reflect growth in revenues, excluding the COVID-19 revenue impact.

OPKO Health's (OPK) Q1 Earnings Miss Estimates, Sales Down Y/Y

OPKO Health's (OPK) first-quarter results reflect soft performances despite robust RAYALDEE sales and strength in the Pharmaceuticals segment.

McKesson (MCK) Q4 Earnings Miss Estimates, Revenues Up Y/Y

McKesson's (MCK) fourth-quarter fiscal 2024 results showcase growth in the U.S. Pharmaceutical while lower COVID-related sales hurt the Medical Surgical Solutions segment.

Nevro's (NVRO) Q1 Earnings and Sales Beat Estimates, Margins Up

Nevro's (NVRO) first-quarter earnings and revenues surpass their respective Zacks Consensus Estimate. The company incurs a loss in the operating level.

Inspire Medical (INSP) Q1 Earnings Beat, Gross Margin Up

Inspire Medical's (INSP) both geographic segments witness strong revenue growth in the first quarter.

Masimo (MASI) Q1 Earnings Beat Estimates, '24 EPS View Up

Masimo's (MASI) Q1 healthcare revenues reflect strong sensor orders, which were completely offset by lower capital equipment purchases. Sensor production in Malaysia is likely to improve Healthcare gross margin.

Fresenius Medical (FMS) Q1 Earnings Beat, Operating Margin Up

Fresenius Medical's (FMS) first-quarter revenues suffer due to unfavorable currency movement. However, the company's transformational plans continue to benefit its operating income.

Integra's (IART) Q1 Earnings Match Estimates, Margins Down

Strong demand for Integra's (IART) diverse portfolio of leading brands and continued successful market adoption of CereLink contributes to its revenues.

Quest Diagnostics (DGX) Grows in Digital Pathology With New Deal

Quest Diagnostics' (DGX) pathology laboratories nationwide are set to get a boost with PathAI's AISight digital pathology image management system.

Shockwave Medical (SWAV) Q1 Earnings Beat, Revenues Rise Y/Y

Shockwave Medical's (SWAV) first-quarter results reflect robust revenue growth and gross margin expansion amid JNJ entering into a definitive agreement to acquire the company.

GE HealthCare (GEHC) Unveils Head-Only MR Scanner SIGNA MAGNUS

GE HealthCare's (GEHC) new SIGNA MAGNUS can delve deep into the brain's microstructure, microvasculature and function, providing researchers with a clearer picture of neurological diseases and disorders.

Is Align Technology (ALGN) Outperforming Other Medical Stocks This Year?

Here is how Align Technology (ALGN) and Aadi Bioscience, Inc. (AADI) have performed compared to their sector so far this year.

Avanos (AVNS) Q1 Earnings & Revenues Surpass Estimates

Avanos' (AVNS) first-quarter results show strong bottom-line improvement along with decent growth in segmental revenues.

Surmodics (SRDX) Q2 Earnings Top Estimates, '24 View Up

Surmodics (SRDX) fiscal second-quarter results showcase growth in the medical device segment. The bottom line improves and beats the Zacks Consensus Estimate.

Hologic's (HOLX) Q2 Earnings Beat Estimates, 2024 View Up

Hologic's (HOLX) GYN Surgical Q2 performance was driven by strong results from MyoSure and Fluent Fluid Management.

Lantheus (LNTH) Q1 Earnings Surpass Estimates, Gross Margin Up

Lantheus' (LNTH) robust revenues from the majority of its segments drive its first-quarter performance.

DaVita (DVA) Q1 Earnings & Revenues Top Estimates, Margins Up

DaVita's (DVA) robust segmental revenues drive its first-quarter performance.

Bruker (BRKR) Q1 Earnings Surpass Estimates, Margins Decline

Bruker's (BRKR) BioSpin segment witnessed growth across biopharma, academic government and industrial research in the first quarter of 2024.

Teleflex (TFX) Q1 Earnings Beat Estimates, Margins Rise

Teleflex's (TFX) first-quarter 2024 results reflect growth across the majority of the company's product families in EMEA.

GE Healthcare's (GEHC) Revolution RT to Aid Cancer Treatment

GE Healthcare (GEHC) unveils Revolution RT, along with other upgrades, from its portfolio during the ESTRO 2024 Congress.